Payment overview · 2025
General Payments
$1,146.27
56 reported records · 21 companies
Healthcare provider profile · identity verified
John Glenn Creel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WALTERBORO, SC · NPI 1992708309
Verified facts
What the public records show
CMS Open Payments records show John Glenn Creel, M.D. received $1,146.27 in general payments during 2025 across 56 reported records.
Exact Sciences Corporation accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Paxlovid, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $172.99 | 15.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.07 | 14.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $140.55 | 12.3% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $106.53 | 9.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $98.26 | 8.6% | 6 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $68.82 | 6.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $66.00 | 5.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $63.49 | 5.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.63 | 2.6% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.61 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.64 | 2.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.77 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.82 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.72 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.78 | 1.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.14 | 1.7% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $18.87 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.33 | 1.6% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $17.29 | 1.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.75 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.21 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,146.27 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $154.20 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $140.55 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $140.55 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $111.29 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $106.53 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $81.40 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.52 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $68.82 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $66.00 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $63.49 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 326 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
149 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
326 | 95 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
326 | 95 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
119 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
145 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
207 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 966 | 317 |
| Amlodipine Besylate | Amlodipine Besylate | 721 | 233 |
| Montelukast Sodium | Montelukast Sodium | 552 | 192 |
| Gabapentin | Gabapentin | 541 | 192 |
| Losartan Potassium | Losartan Potassium | 429 | 147 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 127 |
| Omeprazole | Omeprazole | 390 | 134 |
| Duloxetine Hcl | Duloxetine Hcl | 374 | 119 |
| Furosemide | Furosemide | 342 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 329 | 77 |
| Jardiance | Empagliflozin | 326 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 96 |
| Prednisone | Prednisone | 269 | 170 |
| Metformin Hcl | Metformin Hcl | 265 | 97 |
| Lisinopril | Lisinopril | 253 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 251 | 103 |
| Ezetimibe | Ezetimibe | 250 | 77 |
| Famotidine | Famotidine | 230 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 71 |
| Trazodone Hcl | Trazodone Hcl | 211 | 68 |
| Baclofen | Baclofen | 209 | 87 |
| Eliquis | Apixaban | 207 | 43 |
| Carvedilol | Carvedilol | 194 | 60 |
| Januvia | Sitagliptin Phosphate | 194 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 190 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 88 |
| Diclofenac Sodium | Diclofenac Sodium | 181 | 69 |
| Meloxicam | Meloxicam | 179 | 62 |
| Ozempic | Semaglutide | 161 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 43 |
| Farxiga | Dapagliflozin Propanediol | 149 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 50 |
| Trulicity | Dulaglutide | 145 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 45 |
| Spironolactone | Spironolactone | 125 | 42 |
| Mounjaro | Tirzepatide | 119 | 28 |
| Buspirone Hcl | Buspirone Hcl | 114 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 111 | 35 |
| Potassium Chloride | Potassium Chloride | 110 | 54 |
| Metformin Hcl Er | Metformin Hcl | 107 | 50 |
| Fluconazole | Fluconazole | 106 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 26 |
| Allopurinol | Allopurinol | 98 | 30 |
| Glipizide | Glipizide | 98 | 32 |
| Tramadol Hcl | Tramadol Hcl | 97 | 44 |
| Entresto | Sacubitril/Valsartan | 90 | 19 |
| Azithromycin | Azithromycin | 88 | 80 |
| Valsartan | Valsartan | 88 | 32 |
| Mupirocin | Mupirocin | 87 | 53 |
| Mirtazapine | Mirtazapine | 86 | 35 |
| Donepezil Hcl | Donepezil Hcl | 85 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 70 |
| Glipizide Er | Glipizide | 84 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 27 |
| Meclizine Hcl | Meclizine Hcl | 82 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 74 |
| Linzess | Linaclotide | 77 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 23 |
| Clonidine Hcl | Clonidine Hcl | 73 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 66 | 32 |
| Methocarbamol | Methocarbamol | 65 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 23 |
| Memantine Hcl | Memantine Hcl | 63 | 24 |
| Ibuprofen | Ibuprofen | 60 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 18 |
| Nystatin | Nystatin | 57 | 25 |
| Topiramate | Topiramate | 57 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 13 |
| Sertraline Hcl | Sertraline Hcl | 56 | 21 |
| Ketoconazole | Ketoconazole | 52 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 33 |
| Calcitriol | Calcitriol | 49 | 26 |
| Sucralfate | Sucralfate | 49 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 16 |
| Bumetanide | Bumetanide | 46 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 45 | 19 |
| Colchicine | Colchicine | 44 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 43 | 37 |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 13 |
| Xarelto | Rivaroxaban | 41 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | 11 |
| Cephalexin | Cephalexin | 39 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 19 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | 12 |
| Atenolol | Atenolol | 37 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 16 |
| Celecoxib | Celecoxib | 35 | 11 |
| Levofloxacin | Levofloxacin | 35 | 34 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 25 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | 17 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 13 |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tri-Lo-Mili | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,146.27 · 56 records | Exact Sciences Corporation | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, FABRAZYME, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, Korlym, NEXPLANON, NUPLAZID, OTEZLA, Ozempic, PAXLOVID, QUTENZA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, VYVGART HYTRULO, Veozah, YUPELRI | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error